CIVILICA We Respect the Science
Publisher of Iranian Journals and Conference Proceedings
Paper
title

The role of personalized medicine in fluoropyrimidine-based chemotherapy: Identification of predictive markers in chemotherapy treatment

Credit to Download: 0 | Page Numbers 2 | Abstract Views: 91
Year: 2016
COI code: IPMCMED01_175
Paper Language: English

How to Download This Paper

For Downloading the Fulltext of CIVILICA papers please visit the orginal Persian Section of website.

Authors The role of personalized medicine in fluoropyrimidine-based chemotherapy: Identification of predictive markers in chemotherapy treatment

  Mohamad Hadi Abasian - National institute of genetic engineering and biotechnology (nigeb)
Bahareh Abbasi - Department of Medical Genetic, Medical Biotechnology Ins., National Institute of Genetic Engineering and iotechnology (NIGEB), Tehran, IR Iran
  Nafiseh Ansarinejad - Department of Hematology and Oncology, Hazrat Rasool-e Akram Hospital, Iran University of Medical Sciences, Tehran, IR Iran
  Farshid Fardad - Department of Hematology and Oncology, Hazrat Rasool-e Akram Hospital, Iran University of Medical Sciences, Tehran, IR Iran

Abstract:

Introduction & Aim: The fluoropyrimidine drug 5-fluorouracil (5-FU) and the prodrug capecitabine, have been extensively used for treatment of many types of cancer including colorectal, gastric and head and neck. Approximately 10% of the patients suffer from severe fluoropyrimidine-induced toxicity, like diarrhea, mucositis, myelosuppression and hand-foot syndrome. This may lead to dose reduction and treatment discontinuation. Pharmacogenetics research could be useful for identification of predictive markers in chemotherapy treatment. Methods: Germline DNA was extracted from 83 cancer patients treated with fluoropyrimidine-based chemotherapy in Hazrat Rasool-e Akram Hospital . In this study, we genotyped three polymorphisms in dihyropyrimidine dehydrogenase gene (rs3918290),(rs67376798),(rs55886062) and two polymorphisms, The variable number of tandem repeat (VNTR) polymorphism (rs45445694) and 6-bp insertion/deletion polymorphism(rs151264360) in thymidylate synthase gene. These genetic markers were correlated with toxicity to treatment. 5-FU-related toxicities such as Anemia, febrile neutropenia, neurotoxicity, vomiting, nausea and mucositis were evaluated according to NCI-CTC criteria version 4.0 . Results: DPYD gene polymorphisms was not observed in this study. The frequency of the TYMS +6 bp allele was 40.35% and the -6 bp allele was 59.65% in this study. And frequency of VNTR 2R allele was 48.75% and 3R allele was 51.15% .Toxicity grade two diarrhea,mucositis,nausea,vomiting and neurotoxicity are 2.2%,24.1%,15.7%,6% and 51.8%, respectively . Thymidylate synthase ins/del polymorphisms was significantly associated with increased grade three Neurotoxicity (p=0.02) . Conclusion: A pharmacogenetic approach could be a useful strategy for personalizing chemotherapy in cancer patients. Although rare DPYD polymorphisms was not observed in our study, according to large population studies, DPYD gene polymorphisms could be used as a predictive biomarker for efficacy of fluoropyrimidene-based chemotherapy . This study is currently underway to evaluate the role of thymidylate synthase polymorphisms in Progression-Free Survival, and Overall Survival in cancer patients.

Keywords:

chemotherapy,fluoropyrimidines, 5-fluorouracil,colorectal cancer, gastric cancer , dihydropyrimidine ehydrogenase, pharmacogenetics

Perma Link

https://www.civilica.com/Paper-IPMCMED01-IPMCMED01_175.html
COI code: IPMCMED01_175

how to cite to this paper:

If you want to refer to this article in your research, you can easily use the following in the resources and references section:
Abasian, Mohamad Hadi; Bahareh Abbasi; Nafiseh Ansarinejad & Farshid Fardad, 2016, The role of personalized medicine in fluoropyrimidine-based chemotherapy: Identification of predictive markers in chemotherapy treatment, First Personal Medical Congress, تهران, دانشگاه علوم پزشكي ايران - پژوهشكده ملي مهندسي ژنتيك و زيست فناوري ايران، مركز همكاري هاي فناوري و نوآوري هاي رياست جمهوري, https://www.civilica.com/Paper-IPMCMED01-IPMCMED01_175.htmlInside the text, wherever referred to or an achievement of this article is mentioned, after mentioning the article, inside the parental, the following specifications are written.
First Time: (Abasian, Mohamad Hadi; Bahareh Abbasi; Nafiseh Ansarinejad & Farshid Fardad, 2016)
Second and more: (Abasian; Abbasi; Ansarinejad & Fardad, 2016)
For a complete overview of how to citation please review the following CIVILICA Guide (Citation)

Scientometrics

The University/Research Center Information:
in University Ranking and Scientometrics the Iranian universities and research centers are evaluated based on scientific papers.

Research Info Management

Export Citation info of this paper to research management softwares

New Related Papers

Iran Scientific Advertisment Netword

Share this paper

WHAT IS COI?

COI is a national code dedicated to all Iranian Conference and Journal Papers. the COI of each paper can be verified online.